A randomized trial depicted that the nitazoxanide-based therapeutic regimen (nitazoxanide, proton pump inhibitor, and clarithromycin) yielded greater Helicobacter pylori (H. pylori) elimination rates compared to the standard treatment (metronidazole, omeprazole, and clarithromycin) in children and adolescents. D Shawky et al. aimed to assess the effectiveness of novel nitazoxanide-based therapeutic interventions for H. pylori infection versus recent metronidazole-based treatments to address the issue of elevating metronidazole resistance.

Overall, 100 subjects diagnosed with H. pylori infection were enrolled and randomly segregated into 2 groups. Patients in group I were given nitazoxanide-based triple therapy (clarithromycin, proton pump inhibitor, and nitazoxanide) while patients in group II were administered standard therapy (clarithromycin, omeprazole, and metronidazole) for fourteen days. All patients underwent H. pylori stool antigen testing, laboratory assessments (renal and liver function tests, complete blood count), full clinical examination, and careful history taking on recruitment and following 6 weeks of intervention.

Notably, 84% of patients in the metronidazole group and 92% of patients in the nitazoxanide group recovered from infection. No substantial difference was noted between nitazoxanide and metronidazole groups. A 54% lower risk of resistant infection (odds ratio: 0.5) was witnessed in patients in the nitazoxanide group than those in the metronidazole group. Therefore, the nitazoxanide-based therapeutic regimen is promising for the management of H. pylori infection.